Edition:
India

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

394.10INR
3:49pm IST
Change (% chg)

Rs9.05 (+2.35%)
Prev Close
Rs385.05
Open
Rs386.70
Day's High
Rs396.10
Day's Low
Rs382.05
Volume
1,480,341
Avg. Vol
2,351,592
52-wk High
Rs515.00
52-wk Low
Rs332.75

Chart for

About

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth... (more)

Overall

Beta: 0.50
Market Cap(Mil.): Rs511,564.19
Shares Outstanding(Mil.): 1,023.74
Dividend: 3.20
Yield (%): 0.96

Financials

  CADI.NS Industry Sector
P/E (TTM): 41.67 30.93 32.76
EPS (TTM): 11.99 -- --
ROI: -- 15.07 14.61
ROE: -- 16.59 16.33

BUZZ-Weak Q1 expected for Cadila, Lupin; improving trends for Cipla, Sun - Credit Suisse

** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)

09 Jul 2018

BRIEF-Cadila Healthcare Says Zydus Cadila Got USFDA Nod For Drug to Treat Parkinson's Symptoms

* ZYDUS CADILA RECEIVES FINAL APPROVAL FROM USFDA FOR CARBIDOPA TABLETS

10 May 2018

BRIEF-Cadila Healthcare Gets Exit Price For Sale Of Shares To Bayer (South East Asia)

* CADILA HEALTHCARE - GOT EXIT PRICE FOR SALE OF SHARES TO BAYER (SOUTH EAST ASIA) PTE LTD IN TERMS OF JV AGREEMENT Source text: http://bit.ly/2HNe3Uu Further company coverage:

02 May 2018

BRIEF-Cadila Healthcare Says Zydus Received Final Approval From USFDA For Bumetanide Tablets USP

* SAYS ZYDUS RECEIVED FINAL APPROVAL FROM USFDA FOR BUMETANIDE TABLETS USP Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Cadila Healthcare To Sell 12.5 Mln Shares Of JV To Bayer (South East Asia)

* SAYS CO IS SELLING 12.5 MILLION SHARES OF JV TO BAYER (SOUTH EAST ASIA) PTE BY EXECUTING SHARE PURCHASE DEAL Source text - https://reut.rs/2r4g6ft Further company coverage:

27 Apr 2018

BRIEF-Cadila Healthcare Says Zydus Gets U.S. FDA Final Nod For Methylprednisolone Tablets USP, Cinacalcet Hydrochloride Tablets

* SAYS ZYDUS GETS FINAL APPROVAL FROM USFDA FOR METHYLPREDNISOLONE TABLETS USP AND CINACALCET HYDROCHLORIDE TABLETS Source text - http://bit.ly/2Hry5Yw Further company coverage:

25 Apr 2018

BRIEF-Cadila Healthcare Says Zydus Gets Final Approval From U.S. FDA For Diclofenac Sodium Topical Solution

* SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR DICLOFENAC SODIUM TOPICAL SOLUTION

19 Apr 2018

BUZZ-CY 2018 to be volatile for Indian stock markets - Citi

** Calendar year 2018 will be volatile for Indian stock markets, says Citi

09 Apr 2018

MEDIA-India's Cadila Healthcare appeals against Delhi High Court order refusing to stay CCI verdict - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

04 Apr 2018

BRIEF-India's Cadila Healthcare Says No Observation Issued For Topical Unit

* SAYS TOPICAL FACILITY SUCCESSFULLY COMPLETES USFDA INSPECTION

28 Mar 2018

Earnings vs. Estimates